Loading...
Please wait, while we are loading the content...
Similar Documents
Protected Graft Copolymer (PGC) Basal Formulation of Insulin as Potentially Safer Alternative to Lantus® (Insulin-Glargine): A Streptozotocin-Induced, Diabetic Sprague Dawley Rats Study
| Content Provider | Semantic Scholar |
|---|---|
| Author | Reichstetter, Sandra Castillo, G. Manuel Ángel Lai, Manshun Nishimoto-Ashfield, Akiko Banerjee, Aryamitra A. Bogdanov, Alexei Lyubimov, Alexander V. Bolotin, Elijah M. |
| Copyright Year | 2011 |
| Abstract | AbstractPurposeTo develop a long-acting formulation of native human insulin with a similar pharmacodynamics (PD) profile as the insulin analogue insulin glargine (Lantus®, Sanofi-Aventis) with the expectation of retaining native human insulin’s superior safety profile as insulin glargine is able to activate the insulin-like growth factor 1 (IGF-1) receptor and is linked to a number of malignancies at a higher rate than regular human insulin.MethodsDevelopment of protected graft copolymer (PGC) excipients that bind native human insulin non-covalently and testing blood glucose control obtained with these formulations in streptozotocin-induced diabetic Sprague Dawley rats compared to equally dosed insulin glargine.ResultsPGC-formulations of native human insulin are able to control blood glucose to the same extent and for the same amount of time after s.c. injection as the insulin analogue insulin glargine. No biochemical changes were made to the insulin that would change receptor binding and activation with their possible negative effects on the safety of the insulin.ConclusionFormulation with the PGC excipient offers a viable alternative to biochemically changing insulin or other receptor binding peptides to improve PD properties. FigureBlood glucose development in STZ-diabetic Sprague Dawley rats after s.c. injection of 1 mg/kg regular human insulin formulated with formulations 605c, 421a, and 421b, or an equivalent dose of insulin glargine. |
| Starting Page | 1033 |
| Ending Page | 1039 |
| Page Count | 7 |
| File Format | PDF HTM / HTML |
| DOI | 10.1007/s11095-011-0646-8 |
| PubMed reference number | 22203325 |
| Journal | Medline |
| Volume Number | 29 |
| Alternate Webpage(s) | http://pharmain.com/wp-content/uploads/2014/12/Reichstetter-et-al_insulin_Dec2011.pdf |
| Alternate Webpage(s) | https://doi.org/10.1007/s11095-011-0646-8 |
| Journal | Pharmaceutical Research |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
